Moxifloxacin

# Moxifloxacin ## Overview - **Classification**: Fourth-generation Fluoroquinolone antibiotic. - **Mechanism**: Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, essential enzymes for DNA replication, transcription, repair, and recombination. This leads to bacterial cell death. ## Primary Indications 1. **Community-Acquired Pneumonia (CAP)** - Caused by susceptible organisms. 2. **Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)** - When other options are unsuitable. 3. **Acute Bacterial Sinusitis (ABS)** - When other options are unsuitable. 4. **Complicated Skin and Skin Structure Infections (cSSSI)** - Including diabetic foot infections. 5. **Complicated Intra-abdominal Infections (cIAI)** - Including polymicrobial infections. ## Adult Dosing ### Standard Dosing **Community-Acquired Pneumonia (CAP), ABECB, ABS, cSSSI, cIAI** - **Dose**: **400 mg** - **Frequency**: Once daily - **Route**: Oral or Intravenous (IV) - **Duration**: Typically 5-21 days depending on indication and severity (e.g., CAP 7-14 days; ABECB 5 days) ### Dose Adjustments - **Renal Impairment**: No dose adjustment necessary for any degree of renal impairment, including ESRD or dialysis. - **Hepatic Impairment**: No dose adjustment necessary for mild to moderate hepatic impairment (Child-Pugh A or B). Use with caution in severe impairment (Child-Pugh C) due to limited data. - **Elderly Patients**: No specific dose adjustment needed. Monitor for increased susceptibility to adverse effects (e.g., QTc prolongation, tendinopathy). ## Pediatric Dosing **⚠️ IMPORTANT**: Moxifloxacin is **not routinely recommended** for pediatric patients (<18 years) due to the risk of irreversible cartilage damage (arthropathy) and other serious adverse effects. Its use is limited to very specific, severe, life-threatening infections where alternative therapies are not available or are ineffective (e.g., bioterrorism-related infections like anthrax or plague). Clinical decision should be made only after careful risk-benefit assessment by an infectious disease specialist. ### Neonates (0-28 days) - **Dose**: Not routinely recommended. Use only in extreme, life-threatening situations where benefit clearly outweighs risk, and no alternatives exist. - **Frequency**: N/A - **Maximum**: N/A - **Special Notes**: High risk of arthropathy. Avoid use. ### Infants (1-12 months) - **Dose**: Not routinely recommended for common infections. For *specific bioterrorism-related infections* (e.g., anthrax post-exposure prophylaxis), **10 mg/kg**. - **Frequency**: Once daily - **Maximum**: **400 mg/day** (based on anthrax prophylaxis guidelines). - **Special Notes**: Use only when no safer effective alternatives for life-threatening conditions. ### Children (1-12 years) - **Dose**: Not routinely recommended for common infections. For *specific bioterrorism-related infections* (e.g., anthrax post-exposure prophylaxis), **10 mg/kg**. - **Frequency**: Once daily - **Maximum**: **400 mg/day**. - **Special Notes**: Consider risks versus benefits carefully. Limited data on long-term safety. ### Adolescents (13-18 years) - **Dose**: Not routinely recommended for common infections due to arthropathy risk. If used for *specific severe infections* (e.g., anthrax post-exposure prophylaxis), **400 mg** if >45 kg. - **Frequency**: Once daily - **Maximum**: **400 mg/day**. - **Special Notes**: Adult dosing may be considered for adolescents ≥45 kg in very specific, severe cases where benefits outweigh risks and alternatives are lacking. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to moxifloxacin or other fluoroquinolones. - **Absolute**: History of quinolone-associated tendinopathy or tendon rupture. - **Absolute**: Known QTc prolongation (congenital or acquired). - **Absolute**: Uncorrected hypokalemia or hypomagnesemia. - **Relative**: History of Torsades de Pointes. - **Relative**: Concomitant use with other QTc-prolonging drugs. ### Common Adverse Effects - **Common (1-10%)**: Nausea, diarrhea, headache, dizziness, abdominal pain, constipation, insomnia. - **Serious but Rare**: Tendinopathy/tendon rupture (Achilles, rotator cuff, hand), peripheral neuropathy (irreversible), QTc prolongation leading to Torsades de Pointes, C. difficile-associated diarrhea (CDAD), dysglycemia (hypoglycemia/hyperglycemia), psychiatric effects (hallucinations, confusion, depression), aortic aneurysm/dissection, severe hypersensitivity reactions (e.g., SJS). ### Key Drug Interactions - **QTc prolonging drugs** (e.g., Class IA/III antiarrhythmics, TCAs, macrolides, antipsychotics): Avoid co-administration due to increased risk of Torsades de Pointes. - **Antacids, Sucralfate, Mineral Supplements (Mg, Al, Ca, Fe, Zn)**: Chelation reduces moxifloxacin absorption. Administer moxifloxacin at least 4 hours before or 8 hours after these agents. - **Warfarin**: May enhance anticoagulant effect. Monitor INR closely. - **Insulin/Oral Hypoglycemics**: Increased risk of dysglycemia (both hypo- and hyperglycemia). Monitor blood glucose levels closely in diabetic patients. - **NSAIDs**: May increase CNS stimulation and risk of seizures; use with caution. ## Monitoring & Follow-up - **Before Treatment**: - Assess for history of QTc prolongation, tendinopathy, or psychiatric disorders. - Baseline electrolytes (K+, Mg2+) if risk factors for abnormalities. - **During Treatment**: - Monitor for signs/symptoms of tendinopathy (pain, swelling, inflammation). Discontinue if suspected. - Monitor for signs of peripheral neuropathy (pain, burning, tingling, numbness). Discontinue if suspected. - Monitor blood glucose in diabetic patients. - Observe for psychiatric changes (agitation, confusion, hallucinations). - Monitor ECG if risk factors for QTc prolongation or with concomitant QTc-prolonging drugs. - Monitor for signs of C. difficile infection (severe diarrhea). - **Clinical Signs**: Counsel patients to report any tendon pain, numbness/tingling, severe diarrhea, or mood changes immediately. ## Clinical Pearls - 💡 **Tendon Rupture Risk**: Counsel patients on the immediate discontinuation and seeking medical attention if they experience any tendon pain, swelling, or inflammation. Risk increases with age, corticosteroids, and kidney disease. - 💡 **Administration**: Can be taken with or without food. Avoid taking with dairy products or calcium-fortified juices *just at the time of the dose* as they can reduce absorption. - 💡 **Photosensitivity**: Counsel patients to avoid excessive sun exposure and use sunscreen due to potential photosensitivity. - 💡 **CNS Effects**: Warn patients about potential for dizziness or lightheadedness that may impair ability to drive or operate machinery. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.